Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
107.81
(
0.31%
)
Bitcoin
76,943.58
(
-0.60%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 171434

Wednesday, 06/10/2015 2:12:30 PM

Wednesday, June 10, 2015 2:12:30 PM

Post# of 257580
MRK-Samsung/BIIB*—Phase-3 trials for Enbrel and Remicade FoBs met primary endpoint:

http://finance.yahoo.com/news/merck-samsung-bioepis-announce-pivotal-124600445.html

The five FoBs in this collaboration are:

• Enbrel [worldwide except US/EU/Japan]
• Remicade [worldwide except EU/Russia/Turkey]
• Humira [worldwide except EU/Russia/Turkey]
• Herceptin [worldwide]
• Lantus [worldwide]

Samsung Bioepis is conducting the trials in all of the above programs except Lantus, where MRK has the lead role.

*d/b/a Samsung Bioepis.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today